Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma

Thelen,Paul; Krahn,Lisa; Bremmer,Felix; Strauss,Arne; Brehm,Ralph; Loertzer,Hagen

doi:10.3892/ijmm.2012.1221

Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma

Authors:
- Paul Thelen
- Lisa Krahn
- Felix Bremmer
- Arne Strauss
- Ralph Brehm
- Hagen Loertzer
View Affiliations

Affiliations: Department of Urology, University Medical Center Göttingen, Georg-August-University, D-37075 Göttingen, Germany, University of Veterinary Medicine Hannover, Foundation, D-30173 Hannover, Germany, Institute of Pathology, University Medical Center Göttingen, Georg-August-University, D-37075 Göttingen, Germany
Published online on: December 21, 2012 https://doi.org/10.3892/ijmm.2012.1221
Pages: 339-346

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. LNCaP cells were treated with valproate, temsirolimus or a combination of both. The proliferation rates and the expression of key markers of tumorigenesis were evaluated. In in vivo experiments, LNCaP cells were implanted into immune-suppressed male nude mice. Mice were treated with valproate (per os), temsirolimus (intravenously) or with a combination of both. Tumor volumes were calculated and mRNA expression was quantified. The incubation of LNCaP cells with the combination of valproate and temsirolimus resulted in a decrease of cell proliferation with an additive effect of both drugs in comparison to the single treatment. In particular, the combined application of valproate and temsirolimus led to a significant upregulation of insulin-like growth factor-binding protein-3 (IGFBP-3), which mediates apoptosis and inhibits tumor cell proliferation. In the mouse model, we found no significant differences in tumor growth between the different treatment arms but immunohistological analyses showed that tumors treated with a combination of valproate and temsirolimus, but not with the single drugs alone, exhibited a significant lower proliferation capacity.

View Figures

View References

1.	Börgermann C, Loertzer H, Luboldt HJ, et al: PSA - Quo vadis? Urologe A. 48:1012–1014. 2009.(In German).
2.	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Centenera MM, Harris JM, Tilley WD and Butler LM: The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol. 22:2373–2382. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Knudsen KE and Penning TM: Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 21:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Wang L, Zou X, Berger AD, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 1:62–71. 2009.PubMed/NCBI
6.	Weichert W, Röske A, Gekeler V, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Halkidou K, Gaughan L, Cook S, et al: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 59:177–189. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:6969–6978. 2001.PubMed/NCBI
10.	Xia Q, Sung J, Chowdhury W, et al: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 66:7237–7244. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Thelen P, Schweyer S, Hemmerlein B, et al: Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol. 24:25–31. 2004.PubMed/NCBI
12.	Stettner M, Kaulfuss S, Burfeind P, et al: The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther. 6:2626–2633. 2007. View Article : Google Scholar
13.	Yuan R, Kay A, Berg WJ and Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2:452009. View Article : Google Scholar : PubMed/NCBI
14.	Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
15.	Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
16.	Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Kremer CL, Klein RR, Mendelson J, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Han J, Jogie-Brahim S, Harada A and Oh Y: Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett. 307:200–210. 2011.PubMed/NCBI
20.	Franklin SL, Ferry RJ Jr and Cohen P: Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab. 88:900–907. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Igawa T, Lin FF, Lee MS, et al: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate. 50:222–235. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
23.	Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
24.	Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Yuan PX, Huang LD, Jiang YM, et al: The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 276:31674–31683. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Blaheta RA and Cinatl J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 22:492–511. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Cheng J, Lee EJ, Madison LD and Lazennec G: Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 566:169–172. 2004.
28.	Horvath LG, Henshall SM, Lee CS, et al: Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 61:5331–5335. 2001.PubMed/NCBI
29.	Latil A, Bièche I, Vidaud D, et al: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61:1919–1926. 2001.
30.	Pasquali D, Rossi V, Esposito D, et al: Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab. 86:2051–2055. 2001.PubMed/NCBI
31.	Pasquali D, Staibano S, Prezioso D, et al: Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol. 178:47–50. 2001. View Article : Google Scholar : PubMed/NCBI
32.	Wedel S, Hudak L, Seibel JM, et al: Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci. 88:418–424. 2011. View Article : Google Scholar : PubMed/NCBI
33.	Chen S, Xu Y, Yuan X, et al: Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA. 103:15969–15974. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Azim H, Azim HA Jr and Escudier B: Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol. 5:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
35.	Zhang W, Zhu J, Efferson CL, et al: Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 69:7466–7472. 2009. View Article : Google Scholar : PubMed/NCBI
36.	Fung AS, Wu L and Tannock IF: Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res. 15:5389–5395. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Thompson IM Jr, Leach RJ and Ankerst DP: Prostate cancer detection: a view of the future. Eur Urol. 59:191–193. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 63:317–332. 2002. View Article : Google Scholar : PubMed/NCBI
39.	Jogie-Brahim S, Feldman D and Oh Y: Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 30:417–437. 2009. View Article : Google Scholar : PubMed/NCBI
40.	Marelli MM, Moretti RM, Procacci P, et al: Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the ανβ3 integrin and PI3-K/Akt signaling. Int J Oncol. 28:723–730. 2006.PubMed/NCBI
41.	Goya M, Miyamoto S, Nagai K, et al: Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 64:6252–6258. 2004. View Article : Google Scholar
42.	Wen Y, Hu MC, Makino K, et al: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60:6841–6845. 2000.PubMed/NCBI
43.	Manin M, Baron S, Goossens K, et al: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 366:729–736. 2002.PubMed/NCBI
44.	Rowlands MA, Holly JM, Hamdy F, et al: Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control. 23:347–354. 2012. View Article : Google Scholar : PubMed/NCBI
45.	Shabbeer S, Kortenhorst MS, Kachhap S, et al: Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 67:1099–1110. 2007. View Article : Google Scholar : PubMed/NCBI
46.	Yagi Y, Fushida S, Harada S, et al: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res. 29:1492010. View Article : Google Scholar : PubMed/NCBI
47.	Machado MC, Bellodi-Privato M, Kubrusly MS, et al: Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol. 9:85–92. 2011.PubMed/NCBI
48.	Morgan TM, Pitts TE, Gross TS, et al: RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate. 68:861–871. 2008. View Article : Google Scholar : PubMed/NCBI
49.	Schayowitz A, Sabnis G, Goloubeva O, et al: Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer. 103:1001–1007. 2010. View Article : Google Scholar : PubMed/NCBI
50.	Corcoran NM, Costello AJ and Hovens CM: Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int. 97:1149–1153. 2006. View Article : Google Scholar : PubMed/NCBI